


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4221239/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inhibition of 5-Oxo-6,8,11,14-eicosatetraenoic Acid-Induced Activation of Neutrophils and Eosinophils by Novel Indole OXE Receptor Antagonists. Journal of Medicinal Chemistry, 2014, 57, 364-377.	6.4	27
2	A Reverse Approach to the Total Synthesis of Halichondrin B. Journal of the American Chemical Society, 2021, 143, 9267-9276.	13.7	16
3	Biosynthesis and actions of 5-oxoeicosatetraenoic acid (5-oxo-ETE) on feline granulocytes. Biochemical Pharmacology, 2015, 96, 247-255.	4.4	14
4	Pharmacokinetics and Metabolism of Selective Oxoeicosanoid (OXE) Receptor Antagonists and Their Effects on 5-Oxo-6,8,11,14-eicosatetraenoic Acid (5-Oxo-ETE)-Induced Granulocyte Activation in Monkeys. Journal of Medicinal Chemistry, 2016, 59, 10127-10146.	6.4	14
5	Two Potent OXE-R Antagonists: Assignment of Stereochemistry. ACS Medicinal Chemistry Letters, 2014, 5, 815-819.	2.8	13
6	Stereoselective synthesis of two highly potent 5-oxo-ETE receptor antagonists. Tetrahedron Letters, 2015, 56, 6896-6899.	1.4	11
7	Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys. British Journal of Pharmacology, 2020, 177, 388-401.	5.4	10
8	Inhibition of allergenâ€induced dermal eosinophilia by an oxoeicosanoid receptor antagonist in nonâ€human primates. British Journal of Pharmacology, 2020, 177, 360-371.	5.4	10
9	In vivo α-hydroxylation of a 2-alkylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid in monkeys. Biochemical Pharmacology, 2017, 138, 107-118.	4.4	8
10	Base-dependent formation of cis and trans olefins and their application in the synthesis of 5-oxo-ETE receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3385-3388.	2.2	7
11	Novel Highly Potent and Metabolically Resistant Oxoeicosanoid (OXE) Receptor Antagonists That Block the Actions of the Granulocyte Chemoattractant 5-Oxo-6,8,11,14-Eicosatetraenoic Acid (5-oxo-ETE). Journal of Medicinal Chemistry, 2018, 61, 5934-5948.	6.4	7
12	Metabolism and pharmacokinetics of a potent N-acylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) in rats and monkeys. European Journal of Pharmaceutical Sciences, 2018, 115, 88-99.	4.0	6
13	Targeting the OXE receptor with a selective antagonist inhibits allergenâ€induced pulmonary inflammation in nonâ€human primates. British Journal of Pharmacology, 2022, 179, 322-336.	5.4	6
14	Design, Synthesis, and Biological Evaluation of Tubulysin Analogues, Linker-Drugs, and Antibody–Drug Conjugates, Insights into Structure–Activity Relationships, and Tubulysin–Tubulin Binding Derived from X-ray Crystallographic Analysis. Journal of Organic Chemistry, 2021, 86, 3377-3421.	3.2	5
15	A Highly Convergent Total Synthesis of Norhalichondrin B. Journal of the American Chemical Society, 2021, , .	13.7	5
16	Structure-activity relationship study of β -oxidation resistant indole-based 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4770-4776.	2.2	4
17	Design and synthesis of affinity chromatography ligands for the purification of 5-hydroxyeicosanoid dehydrogenase. Bioorganic and Medicinal Chemistry, 2017, 25, 116-125.	3.0	4
18	Metabolism of anti-inflammatory OXE (oxoeicosanoid) receptor antagonists by nonhuman primates. European Journal of Pharmaceutical Sciences, 2022, 172, 106144.	4.0	1